Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.78 |
| ▸ | PIK3R2 | O00459 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19317553 | 1.00 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL17640771 | 1.00 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL17640644 | 0.89 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL19317551 | 0.88 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL17640645 | 0.88 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL17640761 | 0.88 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL17640744 | 0.86 | PIK3CD (0.79) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL17640735 | 0.86 | PIK3CD (0.79) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL17640762 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL19322363 | 0.80 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611777-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2020-04-07 | — | — | US | disclosed |
| US-20190127391-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LTD (CN) | 2019-05-02 | — | — | US | disclosed |
| US-10208066-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-02-19 | — | — | US | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
| WO-2016045591-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | PIK3R5, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 9/4885PIK3R2 10/4885 |
| US-10208066-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | PIK3CD 2/4885PIK3CG 8/4885PIK3R2 9/4885 |
| US-20190127391-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | PIK3R5, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 9/4885PIK3R2 10/4885 |
| US-10611777-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | PIK3CD 2/4885PIK3CG 8/4885PIK3R2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.